Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  American Journal Of Pediatric Hematology/Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 3526939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IgG4 as a blocking antibody

  1983cited by this paper
• Honey bee venom specific immunoglobulin G4 in honey bee sting allergic patients and bee keepers.

  1983cited by this paper
• Nonreaginic anaphylactic antibodies in man

  1983cited by this paper
• Reduction of interference by specific IgG with a modified microtiter solid-phase radioimmunoassay to measure honeybee venom IgE.

  1983cited by this paper
• Immunologic evaluation in the prognosis of acute lymphoblastic leukemia. A report from Childrens Cancer Study Group.

  1981cited by this paper
• Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolysate: A possible new prognostic sign in acute myelogenous leukemia

  1981cited by this paper
• Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia.

  1978cited by this paper
• L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.

  1977cited by this paper
• Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia

  1976cited by this paper
• Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia culturs

  1976cited by this paper
• Leukemic serum inhibition of phytohemagglutinin-induced transformation.

  1974cited by this paper
• Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli

  1972cited by this paper
• Immunological responses to L-asparaginase.

  1971cited by this paper
• L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.

  1971cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Use of Universal Premedication in the Prevention of Allergic Reactions to PEGylated-Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

  2026cites this paper
• Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas

  2025cites this paper
• Pegylated Asparaginase‐Induced Liver Injury: A Case‐Based Review and Data From Pharmacovigilance

  2022cites this paper
• Asparagine: A Metabolite to Be Targeted in Cancers

  2021cites this paper
• Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia

  2020cites this paper
• The Outcome of Children With Acute Lymphoblastic Leukemia Without Receiving Sufficient Dose of L-Asparaginase

  2020cites this paper
• Universal premedication and therapeutic drug monitoring for asparaginase‐based therapy prevents infusion‐associated acute adverse events and drug substitutions

  2019cites this paper
• Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment

  2019cites this paper
• l-Asparaginase from Erwinia carotovora: insights about its stability and activity

  2018cites this paper
• Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study

  2017cites this paper
• Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.

  2017cites this paper
• L-asparaginase in the treatment of patients with acute lymphoblastic leukemia

  2016cites this paper
• L-Asparaginase Activity in Cell Lysates and Culture Media of Halophilic Bacterial Isolates

  2016cites this paper
• Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.

  2016cites this paper
• Engineering erythrocytes for the modulation of drugs' and contrasting agents' pharmacokinetics and biodistribution.

  2016cites this paper
• Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.

  2015cites this paper
• Effectiveness of premedication and rapid desensitization in hypersensitivity to L-asparaginase

  2015cites this paper
• Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity

  2015cites this paper
• The Periplasmic Enzyme, AnsB, of Shigella flexneri Modulates Bacterial Adherence to Host Epithelial Cells

  2014cites this paper
• Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia

  2014cites this paper
• Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes

  2014cites this paper
• Expression of CD203c on basophils as a marker of immunoglobulin E-mediated l-asparaginase allergy

  2014cites this paper
• Analysis of the influence of decrease of L-asparaginase activity and hypersensitivity reaction on the treatment outcome in children with acute lymphoblastic leukemia

  2014cites this paper
• How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

  2014cites this paper
• Comparison of Hypersensitivity Reactions to PEG-Asparaginase in Children After Intravenous and Intramuscular Administration

  2013cites this paper
• Acute Lymphoblastic Leukaemia

  2012cites this paper
• Drug Resistance in Leukemia and Lymphoma III

  2012cites this paper
• Microbial L-Asparaginase and its future prospects

  2012cites this paper
• Expanding targets for a metabolic therapy of cancer: L-asparaginase.

  2012cites this paper
• Erwinia asparaginase in pediatric acute lymphoblastic leukemia

  2012cites this paper
• Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.

  2012cites this paper
• Treatment of Acute Lymphoblastic Leukaemia

  2012cites this paper
• Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia

  2011cites this paper
• Asparaginase revisited

  2011cites this paper
• in acute lymphoblastic leukemia Dexamethasone exposure and asparaginase antibodies affect relapse risk

  2011cites this paper
• Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel

  2011cites this paper
• Pharmacogenomics in pediatric leukemia

  2010cites this paper
• Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity

  2010cites this paper
• Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

  2010cites this paper
• A Desensitization Protocol in Children With L-Asparaginase Hypersensitivity

  2010cites this paper
• The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations

  2009cites this paper
• Identifizierung klinisch relevante Epitope der E.coli-Asparaginase mit Hilfe synthetischer Peptide

  2009cites this paper
• Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.

  2009cites this paper
• The ex vivo production of ammonia predicts l-asparaginase biological activity in children with acute lymphoblastic leukemia

  2009cites this paper
• Pegasparaginase: where do we stand?

  2009cites this paper
• First-line treatment of acute lymphoblastic leukemia with pegasparaginase riccardo

  2009cites this paper
• Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.

  2008cites this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cites this paper
• Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients

  2007influential citation
• The anti-asparagines antibodies correlate with l-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

  2007cites this paper
• Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

  2007cites this paper
• Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

  2007cites this paper
• High‐dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy

  2007cites this paper
• Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T.

  2006cites this paper
• Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG‐1941)

  2006cites this paper
• A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.

  2006cites this paper
• Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations

  2005cites this paper
• Asparagine Concentration in Plasma After 2 500 IU/m² PEG-Asparaginase i.v. in Children With Acute Lymphoblastic Leukemia

  2005cites this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cites this paper
• Pegaspargase: a review of clinical studies.

  2003cites this paper
• Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

  2003cites this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cites this paper
• Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.

  2002cites this paper
• Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

  2001cites this paper
• Weekly polyethylene glycol-conjugated l-asparaginase produces better induction remission rates for children with relapsed acute lymphoblastic leukemia than biweekly dosing

  2001cites this paper
• Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.

  2000cites this paper
• L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.

  2000cites this paper
• Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.

  2000cites this paper
• Hypersensitivity o r D evelopment o f A ntibodies t o Asparaginase D oes N ot I mpact T reatment O utcome o f Childhood A cute L ymphoblastic L eukemia

  2000cites this paper
• ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.

  2000cites this paper
• The Three Asparaginases

  1999cites this paper
• Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia.

  1999cites this paper
• The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

  1999cites this paper
• Use of L-asparaginase in childhood ALL.

  1998cites this paper
• Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

  1998cites this paper
• Mechanisms of Treatment Failure in Childhood Acute Lymphoblastic Leukemia: Children’s Cancer Group Initiatives

  1997cites this paper
• Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy.

  1997cites this paper
• Improved pharmacodynamics of l-asparaginase-loaded in human red blood cells

  1996cites this paper
• Tolerance Evaluation of L-asparaginase loaded in red blood cells

  1996cites this paper
• L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.

  1996cites this paper
• [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].

  1995cites this paper
• Pharmacology and drug resistance in childhood lymphoblastic leukemia.

  1990cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress First-line Treatment of Acute Lymphoblastic Leukemia with Pegasparaginase

  year unknowncites this paper